BioMarin Wins FDA Approval of Drug
- Share via
From Bloomberg News
BioMarin Pharmaceutical Inc. said the Food and Drug Administration approved marketing of a therapy against a rare fatal genetic disorder.
The company expects to receive the European Commission’s opinion on the treatment, known as Naglazyme, in the fourth quarter, Novato, Calif.-based BioMarin said. If the opinion is positive, final approval from the European regulator is expected in early 2006, it said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
